FULC Q4 2019 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$411M

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$519,000

Operating Income

-$16M

Net Income

-$16M

EPS (Diluted)

$-0.71

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$5M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$110M

Total Liabilities

$23M

Stockholders' Equity

$87M

Cash & Equivalents

$97M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$519,000	$0	—
Operating Income	-$16M	-$9M	-78.3%
Net Income	-$16M	-$9M	-82.0%